We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03010332
Expanded Access Status : No longer available
First Posted : January 5, 2017
Last Update Posted : April 8, 2019
Sponsor:
Information provided by (Responsible Party):
Atara Biotherapeutics

Study Description
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment options.

Condition or disease Intervention/treatment
CMV Viremia CMV Disease Biological: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)

Detailed Description:

ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.

This is an expanded access protocol designed to provide access of ATA230 to subjects with CMV viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment options. This study will enroll subjects regardless of the underlying susceptibility to CMV, including allogeneic hematopoietic cell transplant (alloHCT), solid organ transplant (SOT), human immunodeficiency virus (HIV), other immunocompromised states, and immune competent subjects who require therapy. Subjects must have active CMV viremia or disease for ≥ 2 weeks despite treatment with antiviral therapy or must be intolerant to antiviral therapy due to treatment-related toxicity or comorbidities such as renal insufficiency or myelosuppression.

ATA230 will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) ATA230 at a dose of 1×10^6 cells/kg (with an acceptable range of 0.8-1.0×10^6 cells/kg) on Days 1, 8, and 15, followed by observation through Day 35.

Study Design
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Expanded Access
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options

Resource links provided by the National Library of Medicine


Interventions
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Biological: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
    ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
    Other Name: ATA230
Eligibility Criteria
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

A subject will be considered eligible to participate in the study if the following inclusion criteria are satisfied:

  1. Has a clinically documented condition associated with CMV disease (eg, interstitial pneumonia, hepatitis, encephalitis, retinitis, colitis) or microbiological evidence of CMV viremia or tissue invasion with CMV infection (as determined by viral culture or levels of CMV DNA in blood or body fluids)

  2. The CMV disease or CMV viremia is characterized by at least one of the following:

    1. CMV disease is persistent or clinically progressing despite ≥ 2 weeks of antiviral therapy
    2. CMV viremia/disease is persistent or increasing (determined by quantitation of blood CMV DNA) despite ≥ 2 weeks of antiviral therapy
    3. A genetic mutation associated with antiviral drug resistance is present
    4. Unable to continue antiviral drugs due to drug-associated toxicity.
  3. No other comparable or satisfactory therapies are available for treatment of CMV
  4. Not eligible for any other trials supporting development of ATA230
  5. For subjects who received an alloHCT, the underlying disease for which the alloHCT was performed is in morphologic remission
  6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3× the upper limit of normal (ULN) and total bilirubin < 2.5×ULN unless caused by CMV
  7. Availability of appropriate ATA230 cell lot (ie, HLA partially-matched and restricted CMV-CTLs)
  8. Subject or subject's representative is willing and able to provide written informed consent

Exclusion Criteria:

A subject will not be eligible to participate in the study if any of the following criteria are met:

  1. Receiving concomitant investigational therapy (co-enrollment in a non-interventional study or a study for follow-up or sample collection only is permitted)
  2. Need for antimetabolite agents (eg, methotrexate), or extracorporeal photopheresis
  3. Antithymocyte globulin or similar anti-T cell antibody therapy ≤ 4 weeks prior to the first dose of ATA230 (on Day 1 of Cycle 1)
  4. Need for vasopressor or ventilator support
  5. Pregnancy, except when ATA230 is clearly needed
  6. Female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception
  7. Inability to comply with study procedures
Contacts and Locations
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03010332


Sponsors and Collaborators
Atara Biotherapeutics
Investigators
Layout table for investigator information
Study Director: Willis Navarro, MD Atara Biotherapeutics
More Information
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Atara Biotherapeutics
ClinicalTrials.gov Identifier: NCT03010332    
Other Study ID Numbers: ATA230-EAP-201
First Posted: January 5, 2017    Key Record Dates
Last Update Posted: April 8, 2019
Last Verified: April 2019
Keywords provided by Atara Biotherapeutics:
Cytomegalovirus
Cytomegalovirus Viremia
Cytomegalovirus Infection
CMV Infection
Hematopoietic Cell Transplant
Solid Organ Transplant
Human Immunodeficiency Virus
Cytomegalovirus Disease
 Hematopoietic Stem Cell Transplant
CMV
CMV syndrome
Cytomegalovirus syndrome
CMV disease
CMV viremia
allogeneic
third-party
Additional relevant MeSH terms:
Layout table for MeSH terms
Viremia
Virus Diseases
Infections
Sepsis
 Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes